Sign in
Taking peopleNo phase

Innate Immune Immunoparalysis and Ventilator-Associated Pneumonia in Critically Ill Elderly Patients

Key facts

Who runs it
Hospital Universitari de Bellvitge
Where
Spain1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
170 people, planned
Started
1 May 2026
Expected to end
31 Jul 2028
Type of study
Observational, 3 groups
Record updated
19 May 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • ≥18 years
  • Mechanical ventilation expected >48h
  • Intubation between 24h pre- and 48h post- ICU admission
  • Informed consent

Who cannot take part

  • High dose steroids at immunosuppressive doses
  • Known severe immunosuppression, including primary immunodeficiency disorders, advanced HIV infection (AIDS), active hematological malignancy under treatment, recent chemotherapy or immunosuppressive therapy
  • Active autoimmune disease
  • Pregnancy
  • End-of-life situation

This trial is currently available in Spain.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This prospective observational cohort study aims to evaluate the role of innate immune immunoparalysis in the development of ventilator-associated pneumonia (VAP) in critically ill mechanically ventilated patients. Immunoparalysis will be assessed through monocyte HLA-DR expression and ex vivo lipopolysaccharide (LPS)-stimulated TNF-α production.

Read full original descriptionShow less

The study will include three cohorts: elderly patients (≥65 years), younger adults (<65 years), and healthy controls. The primary objective is to determine whether the presence, duration, intensity, and trend of immunoparalysis are associated with the incidence of VAP and other ICU-acquired infections. Secondary objectives include characterization of immunoparalysis dynamics, comparison of measurement methods, and evaluation of clinical outcomes.

The 3 groups in the trial

  • Elderly Mechanically Ventilated Patients (≥65 years)

    Critically ill patients aged 65 years or older requiring invasive mechanical ventilation for more than 48 hours. This is the primary study cohort in which innate immune immunoparalysis will be assessed and its association with ventilator-associated pneumonia will be analyzed.

  • Adult Mechanically Ventilated Patients (<65 years)

    Critically ill patients aged 18 to 64 years requiring invasive mechanical ventilation for more than 48 hours, included as a comparison cohort to evaluate age-related differences in immunoparalysis.

  • Healthy Non-Intubated Controls

    Healthy adult volunteers without acute illness and not requiring mechanical ventilation. This group, assessed at a single time point, will serve as a reference population for baseline immunological parameters.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Intensity and Duration of Innate Immune System Immunoparalysis in the Pathophysiology of Ventilator-Associated Pneumonia in Mechanically Ventilated Elderly Patients
Record updated
19 May 2026